SAIL is an observational study to assess the effectiveness, safety profile and real-life prescribing and utilization patterns of a monoclonal antibody in patients with moderate to severe plaque psoriasis in routine clinical practice. Psoriasis affects an estimated 7.8 million adults in Europe and approximately 125 million individuals worldwide, according to the release. Plaque psoriasis appears as red, raised areas of skin covered with flaky white scales that can be itchy and painful.

CVBF is the CRO appointed for submission and monitoring activities for 8 Italian clinical sites that will be authorized in the next months.

About the Author: maria


By Published On: March 26th, 2020Categories: News0 Comments